VirnetX Holding Corp VHC Capitalized Direct And Indirect Research And Development Costs Gross

Capitalized Direct And Indirect Research And Development Costs Gross at other companies

IBT

IbottaIBTA

$22.65M-42.0%

ESABESAB

$22.04M+7.2%

Mineralys Therapeutics, Inc.MLYS

$39.94M-11.2%

BTCSBTCS

$122.52K-26.2%

Angi Inc.ANGI

$2.94M-89.9%

Opko HealthOPK

$195M0.0%

Other financials

Income statement

See full

Revenue-—

Operating income-$4.5M-11.4%

Net income-$4.4M-18.3%

EPS (diluted)-$1.16-14.9%

Balance sheet

See full

Cash & equivalents$14.8M-36.4%

Total debt$7.2M-10.8%

Total equity$18.9M-48.2%

Total assets$26.7M-40.8%

Cash flow

See full

Operating cash flow-$4.3M-10.3%

CapEx$17.0K—

Free cash flow-$5.8M-5.2%

Valuation

See full

Market cap$53.16M+26.6%

Enterprise value$45.6M+39.7%

P/S328.2×-512×

Profitability

See full

Operating margin-12,284.6%-6,084pp

Net margin-11,666.7%-5,775pp

FCF margin-35,193.8%—

Returns & leverage

See full

Return on equity-68.5%+181pp

Debt / equity0.4×+0.2×

Current ratio8.5×-9.2×

Where this comes from

Reported directly by VirnetX Holding Corp in its filing.

Tagged under the XBRL concept vhc:CapitalizedDirectAndIndirectResearchAndDevelopmentCostsGross.

The official record: VirnetX Holding Corp ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about VirnetX Holding Corp 's capitalized direct and indirect research and development costs gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is VirnetX Holding Corp 's capitalized direct and indirect research and development costs gross?: VirnetX Holding Corp (VHC) reported capitalized direct and indirect research and development costs gross of $9.52M in Q4 2025.
What does capitalized direct and indirect research and development costs gross mean?: The total gross investment in research and development activities that have been capitalized, prior to any accumulated amortization or impairment adjustments. This figure represents the total historical cost of developing the company's technology and patent portfolio. It serves as a measure of the cumulative financial commitment to internal innovation and intellectual property creation.